Prolonging β-lactam infusion: A review of the rationale and evidence, and guidance for implementation

Given the sparse antibiotic pipeline and the increasing prevalence of resistant organisms, efforts should be made to optimise the pharmacodynamic exposure of currently available agents. Prolonging the infusion duration is a strategy used to increase the percentage of the dosing interval that free drug concentrations remain above the minimum inhibitory concentration (fT > MIC), the pharmacodynamic efficacy driver for time-dependent antibiotics such as beta-lactams. beta-Lactams, the most commonly prescribed class of antibiotics owing to their efficacy and safety profile, have been the mainstay of therapy since the discovery of penicillin over 60 years ago. Mounting evidence, including the use of population pharmacokinetic modelling and Monte Carlo simulation, suggests that prolonging the infusion time of beta-lactam antibiotics may have advantages over standard infusion techniques, including an enhanced probability of achieving requisite fT > MIC exposures, lower mortality and potentially reductions in infection/antibiotic-related costs. As a result of these favourable attributes, clinical practice guidelines support the use of prolonged-infusion beta-lactams in the treatment of many severe infections. This article discusses the rationale and evidence for prolonging the infusion of beta-lactam antibiotics and provides guidance for the implementation of a prolonged-infusion programme. (C) 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.